TY  - JOUR
TI  - The Evaluation of Clinical Characteristics and Treatment Results of Head and Neck Cancer Patients: Single Center Experience
AB  - Objective The purpose of this study was to review the general characteristics, risk factors, treatment modalities of our head and neck cancer (HNC) patients and to calculate survival of patients, to evaluate the factors affecting our treatment results and survival. Materials and Methods Sixty-seven eligible patients with HNC were evaluated. The study data were obtained from the files of patients diagnosed with HNC who were followed up in Sakarya University Training and Research Hospital between 2011 and 2020. Results The median age at diagnosis was 62 ± 11.40 (range: 19 to 82), 62 in men and 50 in women. The most common location was larynx with 55% frequency. Cigarette and alcohol use rates were 69% and 18%, respectively. Secondary malignancy was observed in 18% (n = 12) of the patients, with the most common secondary malignancy being lung cancer (9%, n = 6). The stages of the patients at the time of diagnosis were 13.45% (n = 9), 22.47% (n = 15), 50.77% (n = 34) and 11.93% (n = 8) stage 1,2,3 and 4, respectively. Forty two percent of the patients had metastases at the time of diagnosis or metastasis developed during follow-up. Metastatic sites were lung in 13 patients (19.45%), lymph node in 10 patients (15%), bone in 7 patients (10.56%), and liver in 1 (1.50%) patient. Local recurrence occurred in 27% (n = 18) of patients. Local recurrence and / or metastasis developed in 50% of 58 patients with stage 1, 2 or 3. The majority of these patients were stage 3 (n = 17 (59%)). While the median disease free survival (DFS) of stage 1-2 patients was 49 ± 29.65 months (range: 0-107 months), the median DFS of stage 3 patients was calculated as 19 ± 10.95 months (range: 0-40 months). Median Progression-free survival (PFS) after first line chemotherapy (CT) with metastatic HNC cancer was 8±3 months (range: 2-14 months). Median overall survival (OS) was calculated 192±83 months in all patients. Conclusion Secondary malignancy development rates were found to be slightly elevated in our study. The total dose of cisplatin concurrent with RT was slightly lower than the other similar studies. The most preferred combination of chemotherapy in metastatic patients was cisplatin/5Fluorouracil/cetuximab. Our PFS results were slightly higher than in the literature.
AU  - DEMİRCİ, ayşe
AU  - hacibekiroglu, ilhan
AU  - bayoglu, ibrahim vedat
AU  - Bilir, Cemil
AU  - Varım, Ceyhun
DO  - 10.31832/smj.784990
PY  - 2021
JO  - Sakarya Tıp Dergisi
VL  - 11
IS  - 1
SN  - 2146-409X
SP  - 129
EP  - 136
DB  - TRDizin
UR  - http://search/yayin/detay/1141932
ER  -